Clinical trials for apilimod and ESK981 are in progress for their efficacy against non-Hodgkin lymphoma [6], prostate cancer [9,72], and renal cell carcinoma [110], as well as SARS-CoV-2 [111], and amyotrophic lateral sclerosis [45,112], Therapeutic applications for chemical inhibitors of PIKFYVE, as well as the phosphoinositide 3-kinases (PI3Ks) and phosphoinositide 4-kinases (PI4Ks) (Figure 3C), have been recently reviewed [113]. This evidence concerns the gene PIKFYVE and prostate cancer.